ROTADON

ROTADON

Rotadon (Powder for oral solution)

(Glucosamine)

 

COMPOSITION

1 sachet contains: glucosamine sulphate (as potassium glucosamine sulphate) 1500 mg.

 

PHARMACOLOGICAL PROPERTIES

PHARMACODYNAMICS

Glucosamine sulphate is a salt of a natural glucosamine amminomonosaccharide that is physiologically present in human body. Glucosamine is used by cartilaginous cells as a base material for synthesis of proteoglycans, glucosaminoglycans and hyaluronic acid of the synovial fluid. Favorably affects the metabolic function within the cartilaginous tissue – intensifies the anabolic and suppresses the catabolic processes, increases the penetration ability of the joint capsule, reconstructs fermentative processes in the cells of a synovial membrane and articular cart. Rotadon stimulates synthesis of the proteoglycans and collagen, increases the production of the components of territorial matrix; at the same time the properties of glucosaminoglycans and proteoglycans are close to the physiological ones. The increase in synthetic activity of cartilaginous cells is accompanied by inhibition of chondrolysis, which is caused by suppressing the activity of chondrolytic proteinases (collagenases, etc.), that makes up the basis of chondroprotective and osteotropic effects.

Glucosamine possesses a moderate anti-inflammatory effect, not connected with the inhibition of synthesis of prostaglandins but realized due to antioxidant activity (by blocking the formation of superoxide radicals) and suppressing the activity of lysosomal ferments. 

Glucosamine initiates the sulphur fixation process in synthesis of chondroitinsulphuric acid and facilitates the process of normal calcium concretion in bone tissue; prevents the harmful action of corticosteroids to cartilage cells and breach in synthesis of glucosaminoglycans, induced by NSAID.

Sulfonate groups also take part in synthesis of glucosaminoglycans and metabolism of the cartilaginous tissue, sulfonate ethers of the lateral chains – in maintaining the elasticity of the cartilage matrix.

Rotadon suppresses the cartilage destruction and reduces the symptoms of osteoarthrosis. 

PHARMACOKINETICS

The drug is quickly absorbed in small intestine. Bioavailability is 25-26%. After the distribution within the tissues the highest concentrations are found in synovial membrane, cartilaginous tissue, liver and kidney. Metabolism takes place in liver with the production of urea, water and carbon dioxide. Intact drug recovery mainly takes place in urine, to a very insignificant extent – in feces. Elimination half-life is equal to 68 hours. 

THERAPEUTIC INDICATIONS 

  •    inflammatory and initial presentation of degenerative - dystrophic limb joints diseases (osteoarthrosis

(osteoarthritis) of a various localization, including arthrosis of knee and coxofemoral joints);

  •    degenerative - dystrophic vertebral column diseases (osteochondrosis, spondylarthrosis, etc.); - chondromalacia patellae;
  •    scapulohumeral periarthritis;
  •    reconstruction of mobility and reduction of painfulness by injuries of joint- ligamentous apparatus; - in complex of rehabilitation actions after joint injuries.

 

 

CONTRADICTIONS

  •   individual intolerability to components of the drug Rotadon (including hypersensitivity in anamnesis); - pregnancy and lactation period;
  •   children aged under 12 years old;
  •   apparent renal disease;
  •   phenylketonuria (contains aspartame)

 

ADVERSE EFFECTS

Gastro-intestinal disorders: in individual cases – flatulence, diarrhea, constipation, pains in the pit of the stomach.

Allergic reactions: in individual cases – nettle rash, itch.

 

DOSAGE AND ADMINISTRATION 

For oral administration.

Rotadon is prescribed to adults in a dosage of 1 sachet (1500 mg) once a day 20 min before meal. The contents of the sachet should be fully dissolved in a glass of warm water and administer immediately after preparation. The duration of treatment is 4-12 weeks. The treatment course can be repeated with the 2 months interval, when necessary.  

 

PACKAGING

Powder for oral solution in sachets.

20 sachets with enclosed leaflet in carton box.